Search / 95 results found

  • Updated

SEATTLE, Sept. 15, 2021 /PRNewswire-PRWeb/ -- InBios International Inc., a leading developer of diagnostic tests for emerging infectious diseases, announced today that it received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its SCoV-2 Detect IgG Rapid Test, a qualitative immunoassay for the detection of IgG antibodies to SARS-CoV-2. This marks InBios' fifth EUA granted for SARS-CoV-2 diagnostics since the beginning of the COVID-19 pandemic.